MA37142B1 - Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine - Google Patents
Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazineInfo
- Publication number
- MA37142B1 MA37142B1 MA37142A MA37142A MA37142B1 MA 37142 B1 MA37142 B1 MA 37142B1 MA 37142 A MA37142 A MA 37142A MA 37142 A MA37142 A MA 37142A MA 37142 B1 MA37142 B1 MA 37142B1
- Authority
- MA
- Morocco
- Prior art keywords
- oxazine
- dihydro
- pyrido
- benzo
- derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/25—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups C12Q1/26 - C12Q1/66
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
L'invention concerne des composés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine de formule (i) et/ou leurs sels et/ou solvates de qualité pharmaceutique, dans laquelle y, v, w, u, q, r
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161579231P | 2011-12-22 | 2011-12-22 | |
PCT/IB2012/057554 WO2013093849A1 (fr) | 2011-12-22 | 2012-12-20 | Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine |
Publications (3)
Publication Number | Publication Date |
---|---|
MA37142A2 MA37142A2 (fr) | 2016-07-29 |
MA37142A3 MA37142A3 (fr) | 2018-05-31 |
MA37142B1 true MA37142B1 (fr) | 2019-07-31 |
Family
ID=47678928
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA37142A MA37142B1 (fr) | 2011-12-22 | 2012-12-20 | Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine |
Country Status (42)
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2702060T3 (es) | 2011-12-22 | 2019-02-27 | Alios Biopharma Inc | Nucleósidos sustituidos, nucleótidos y sus análogos |
CA2859764C (fr) | 2011-12-22 | 2019-12-31 | Novartis Ag | Derives de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine |
AR089284A1 (es) | 2011-12-22 | 2014-08-13 | Galapagos Nv | Dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de trastornos inflamatorios |
US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
TW201422625A (zh) * | 2012-11-26 | 2014-06-16 | Novartis Ag | 二氫-吡啶并-□衍生物之固體形式 |
LT2928896T (lt) * | 2012-11-26 | 2017-09-25 | Novartis Ag | Dihidro-pirido-oksazino darinio kieta forma |
CN105541698B (zh) * | 2015-12-23 | 2018-07-10 | 滨海康杰化学有限公司 | 一种5-溴-2-三氟甲基吡啶的制备方法 |
GB2550437B (en) * | 2016-05-20 | 2021-06-23 | Bugworks Res Inc | Heterocyclic compounds useful as anti-bacterial agents and method for production |
CN111936484A (zh) * | 2017-12-22 | 2020-11-13 | 拉文纳制药公司 | 作为磷脂酰肌醇磷酸激酶抑制剂的色烯并吡啶衍生物 |
CN112867720A (zh) | 2018-08-13 | 2021-05-28 | 豪夫迈·罗氏有限公司 | 作为单酰基甘油脂肪酶抑制剂的新型杂环化合物 |
AU2019395201A1 (en) | 2018-12-06 | 2021-05-20 | Daiichi Sankyo Company, Limited | Cycloalkane-1,3-diamine derivative |
TW202112784A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之𠳭唏并嘧啶衍生物 |
EP4028403B1 (fr) | 2019-09-12 | 2023-11-22 | F. Hoffmann-La Roche AG | Composés de 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one comme inhibiteurs de magl |
CN114728988A (zh) * | 2019-11-20 | 2022-07-08 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的螺(异苯并呋喃氮杂环丁烷)化合物 |
EP4182322B1 (fr) | 2020-07-15 | 2024-04-24 | Chiesi Farmaceutici S.p.A. | Dérivés de pyrido-oxazine en tant qu'inhibiteurs d'alk5 |
WO2023170680A1 (fr) | 2022-03-08 | 2023-09-14 | Equashield Medical Ltd | Station de transfert de fluide dans un système de préparation pharmaceutique robotique |
Family Cites Families (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1524747A (en) | 1976-05-11 | 1978-09-13 | Ici Ltd | Polypeptide |
ATE28864T1 (de) | 1982-07-23 | 1987-08-15 | Ici Plc | Amide-derivate. |
GB8327256D0 (en) | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
US5010099A (en) | 1989-08-11 | 1991-04-23 | Harbor Branch Oceanographic Institution, Inc. | Discodermolide compounds, compositions containing same and method of preparation and use |
TW224941B (fr) | 1989-11-08 | 1994-06-11 | Yamanouchi Pharma Co Ltd | |
NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
TW225528B (fr) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
GB9309716D0 (en) | 1993-05-12 | 1993-06-23 | Zeneca Ltd | Heterocyclic derivatives |
GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
WO1996030347A1 (fr) | 1995-03-30 | 1996-10-03 | Pfizer Inc. | Derives de quinazoline |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US5843901A (en) | 1995-06-07 | 1998-12-01 | Advanced Research & Technology Institute | LHRH antagonist peptides |
TR199800012T1 (xx) | 1995-07-06 | 1998-04-21 | Novartis Ag | Piroloprimidinler ve preparasyon i�in tatbikler. |
US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
BR9708640B1 (pt) | 1996-04-12 | 2013-06-11 | inibidores irreversÍveis de tirosina-cinases e composiÇço farmacÊutica compreendendo os mesmo. | |
CA2258548C (fr) | 1996-06-24 | 2005-07-26 | Pfizer Inc. | Derives tricycliques substitues par phenylamino, destines au traitement des maladies hyperproliferatives |
WO1998008849A1 (fr) | 1996-08-30 | 1998-03-05 | Novartis Aktiengesellschaft | Procede de fabrication d'epothilones, et composes intermediaires obtenus au cours de ce procede |
CA2264908C (fr) | 1996-09-06 | 2006-04-25 | Obducat Ab | Procede de gravure anisotrope de structures dans des materiaux conducteurs |
CA2265630A1 (fr) | 1996-09-13 | 1998-03-19 | Gerald Mcmahon | Utilisation de derives de la quinazoline pour la fabrication d'un medicament destine au traitement de troubles cutanes hyperproliferatifs |
EP0837063A1 (fr) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | Dérivés de 4-aminoquinazoline |
EP0941227B2 (fr) | 1996-11-18 | 2009-10-14 | Gesellschaft für biotechnologische Forschung mbH (GBF) | Epothilone d, mode de preparation et application comme agent cytostatique et phytosanitaire |
US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
GB9721069D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
IL138113A0 (en) | 1998-02-25 | 2001-10-31 | Sloan Kettering Inst Cancer | Synthesis of epothilones, intermediates thereto and analogues thereof |
CN1152031C (zh) | 1998-08-11 | 2004-06-02 | 诺瓦提斯公司 | 具有血管生成抑制活性的异喹啉衍生物 |
KR100851418B1 (ko) | 1998-11-20 | 2008-08-08 | 코산 바이오사이언시즈, 인코포레이티드 | 에포틸론 및 에포틸론 유도체의 생산을 위한 재조합 방법 및 물질 |
EP1056728B1 (fr) | 1998-12-23 | 2007-11-21 | Aventis Pharma Limited | Dihydro-benzo(1,4)oxazines et tetrahydroquinoxalines |
NZ517575A (en) | 1999-09-30 | 2004-04-30 | Neurogen Corp | Certain alkylene diamine-substituted heterocycles |
EP1255743A1 (fr) | 2000-02-01 | 2002-11-13 | Millenium Pharmaceuticals, Inc. | 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINES UTILISEES COMME INHIBITEURS DU FACTEUR Xa |
PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
DE60140201D1 (en) | 2000-11-07 | 2009-11-26 | Novartis Ag | Indolylmaleimidderivative als proteinkinase-c-inhibitoren |
WO2002072049A1 (fr) | 2001-02-27 | 2002-09-19 | Yamanouchi Pharmaceutical Co., Ltd. | Compositions medicamenteuses servant a stimuler la croissance capillaire |
AR035885A1 (es) | 2001-05-14 | 2004-07-21 | Novartis Ag | Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica |
GB0119249D0 (en) | 2001-08-07 | 2001-10-03 | Novartis Ag | Organic compounds |
PE20040079A1 (es) | 2002-04-03 | 2004-04-19 | Novartis Ag | Derivados de indolilmaleimida |
EP1569653A1 (fr) | 2002-12-06 | 2005-09-07 | Warner-Lambert Company LLC | Benzoxazin-3-ones et derives de ceux-ci utilises en tant qu'inhibiteurs de pi3k |
KR20050084224A (ko) | 2002-12-09 | 2005-08-26 | 더 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 야누스 티로신 키나제 3을 선택적으로 저해하는 방법 |
WO2004056820A1 (fr) | 2002-12-20 | 2004-07-08 | Warner-Lambert Company Llc | Benzoxazines et leurs derives en tant qu'inhibiteurs de pi3ks |
CA2514733A1 (fr) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Compositions pharmaceutiques a base d'un co-cristal |
MXPA05010444A (es) | 2003-04-03 | 2005-11-04 | Merck Patent Gmbh | Compuestos de carbonilo. |
EP1678121A4 (fr) | 2003-10-24 | 2007-07-25 | Exelixis Inc | Modulateurs de kinases tao et leurs methodes d'utilisation |
WO2005066156A1 (fr) | 2004-01-12 | 2005-07-21 | Cytopia Research Pty Ltd | Inhibiteurs selectifs de kinases |
JP4018739B2 (ja) | 2004-07-15 | 2007-12-05 | 日本たばこ産業株式会社 | 縮合ベンズアミド化合物及びバニロイド受容体1型(vr1)活性阻害剤 |
DE102004045796A1 (de) | 2004-09-22 | 2006-03-23 | Merck Patent Gmbh | Arzneimittel enthaltend Carbonylverbindungen sowie deren Verwendung |
DE102004047254A1 (de) | 2004-09-29 | 2006-04-13 | Merck Patent Gmbh | Carbonylverbindungen |
WO2006040318A2 (fr) | 2004-10-12 | 2006-04-20 | Applied Research Systems Ars Holding N.V. | Inhibiteurs de kinase gamma p13 pour le traitement de l'anemie |
US20080269204A1 (en) | 2004-11-01 | 2008-10-30 | Tatyana Dyakonov | Compounds and Methods of Use Thereof |
US20060161001A1 (en) | 2004-12-20 | 2006-07-20 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
JP2009507072A (ja) * | 2005-09-07 | 2009-02-19 | ラボラトワール セローノ ソシエテ アノニム | 子宮内膜症の処置のためのpi3k阻害剤 |
TWI385161B (zh) | 2006-02-02 | 2013-02-11 | Mitsubishi Tanabe Pharma Corp | 含氮雜雙環化合物 |
EP2035436B1 (fr) | 2006-06-26 | 2011-05-25 | UCB Pharma S.A. | Dérivés de thiazole à cycle fusionnés en tant qu'inhibiteurs de kinase |
GB0620059D0 (en) | 2006-10-10 | 2006-11-22 | Ucb Sa | Therapeutic agents |
MX337906B (es) | 2006-10-19 | 2016-03-28 | Signal Pharm Llc | Compuestos de heteroarilo, composiciones de los mismos, y su uso como inhibidores de proteina cinasas. |
CN101711241A (zh) | 2007-02-06 | 2010-05-19 | 诺瓦提斯公司 | Pi3-激酶抑制剂和它们的使用方法 |
WO2008109178A1 (fr) | 2007-03-07 | 2008-09-12 | Alantos Pharmaceuticals Holding, Inc. | Inhibiteurs de métalloprotéase contenant une fraction squaramide |
US9603848B2 (en) | 2007-06-08 | 2017-03-28 | Senomyx, Inc. | Modulation of chemosensory receptors and ligands associated therewith |
WO2009026444A1 (fr) | 2007-08-22 | 2009-02-26 | President And Fellows Of Harvard College | Liants aux canaux de la ryanodine et leurs utilisations |
WO2009071895A1 (fr) | 2007-12-04 | 2009-06-11 | Ucb Pharma S.A. | Dérivés thiazole et thiophène fusionnés comme inhibiteurs de kinase |
WO2009157196A1 (fr) | 2008-06-25 | 2009-12-30 | 武田薬品工業株式会社 | Composé amide |
WO2010027002A1 (fr) * | 2008-09-05 | 2010-03-11 | 塩野義製薬株式会社 | Derive de morpholine à cycles condensés ayant une activite inhibitrice de pi3k |
US20100152160A1 (en) | 2008-12-12 | 2010-06-17 | Khamrai Uttam | Novel benzodioxane and benzoxazine derivatives useful as cc chemokine receptor ligands |
JP5730281B2 (ja) | 2009-03-27 | 2015-06-10 | 武田薬品工業株式会社 | ポリ(adp−リボース)ポリメラーゼ(parp)阻害剤 |
TW201102391A (en) | 2009-03-31 | 2011-01-16 | Biogen Idec Inc | Certain substituted pyrimidines, pharmaceutical compositions thereof, and methods for their use |
JP2012531436A (ja) * | 2009-06-25 | 2012-12-10 | アムジエン・インコーポレーテツド | 複素環式化合物およびそれらのpi3k活性阻害剤としての使用 |
JP2013526546A (ja) | 2010-05-13 | 2013-06-24 | アムジエン・インコーポレーテツド | Pde10阻害剤としてのヘテロアリ−ルオキシヘテロシクリル化合物 |
UA112517C2 (uk) | 2010-07-06 | 2016-09-26 | Новартіс Аг | Тетрагідропіридопіримідинові похідні |
KR20120018236A (ko) | 2010-07-23 | 2012-03-02 | 현대약품 주식회사 | 치환된 피리미디닐 유도체 및 이의 제조방법 |
US20140080810A1 (en) | 2010-11-15 | 2014-03-20 | Exelixis, Inc. | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture |
WO2012068106A2 (fr) | 2010-11-15 | 2012-05-24 | Exelixis, Inc. | Benxazépines en tant qu'inhibiteurs de pi3k/mtor et leurs procédés d'utilisation et de fabrication |
CN102731525A (zh) | 2011-04-08 | 2012-10-17 | 上海艾力斯医药科技有限公司 | 苯并吗啉衍生物 |
CA2859764C (fr) | 2011-12-22 | 2019-12-31 | Novartis Ag | Derives de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine |
TW201422625A (zh) | 2012-11-26 | 2014-06-16 | Novartis Ag | 二氫-吡啶并-□衍生物之固體形式 |
-
2012
- 2012-12-20 CA CA2859764A patent/CA2859764C/fr active Active
- 2012-12-20 IN IN4174CHN2014 patent/IN2014CN04174A/en unknown
- 2012-12-20 RS RS20180156A patent/RS56891B1/sr unknown
- 2012-12-20 UA UAA201404866A patent/UA112558C2/uk unknown
- 2012-12-20 ES ES12823036T patent/ES2661864T3/es active Active
- 2012-12-20 MX MX2014007687A patent/MX353342B/es active IP Right Grant
- 2012-12-20 SG SG11201402237WA patent/SG11201402237WA/en unknown
- 2012-12-20 EP EP12823036.4A patent/EP2794600B1/fr active Active
- 2012-12-20 MY MYPI2014001340A patent/MY170922A/en unknown
- 2012-12-20 HU HUE12823036A patent/HUE036953T2/hu unknown
- 2012-12-20 KR KR1020147019952A patent/KR101656592B1/ko active IP Right Grant
- 2012-12-20 JP JP2014548315A patent/JP5903499B2/ja active Active
- 2012-12-20 MA MA37142A patent/MA37142B1/fr unknown
- 2012-12-20 BR BR112014015103-2A patent/BR112014015103B1/pt active IP Right Grant
- 2012-12-20 WO PCT/IB2012/057554 patent/WO2013093849A1/fr active Application Filing
- 2012-12-20 SI SI201231221T patent/SI2794600T1/en unknown
- 2012-12-20 DK DK12823036.4T patent/DK2794600T3/en active
- 2012-12-20 CN CN201280063282.9A patent/CN104011045B/zh active Active
- 2012-12-20 JO JOP/2012/0388A patent/JO3398B1/ar active
- 2012-12-20 AU AU2012356083A patent/AU2012356083B2/en active Active
- 2012-12-20 LT LTEP12823036.4T patent/LT2794600T/lt unknown
- 2012-12-20 EA EA201491247A patent/EA025322B1/ru not_active IP Right Cessation
- 2012-12-20 AP AP2014007658A patent/AP4055A/en active
- 2012-12-20 PT PT128230364T patent/PT2794600T/pt unknown
- 2012-12-20 US US13/721,805 patent/US9539260B2/en active Active
- 2012-12-20 PL PL12823036T patent/PL2794600T3/pl unknown
- 2012-12-20 CR CR20200286A patent/CR20200286A/es unknown
- 2012-12-20 PE PE2014001003A patent/PE20141598A1/es active IP Right Grant
- 2012-12-21 TW TW101149109A patent/TWI577674B/zh not_active IP Right Cessation
- 2012-12-21 UY UY0001034541A patent/UY34541A/es not_active Application Discontinuation
- 2012-12-21 AR ARP120104932A patent/AR089424A1/es active IP Right Grant
-
2013
- 2013-01-30 NO NO13744385A patent/NO2809782T3/no unknown
-
2014
- 2014-05-14 TN TNP2014000210A patent/TN2014000210A1/en unknown
- 2014-06-03 CL CL2014001452A patent/CL2014001452A1/es unknown
- 2014-06-12 IL IL233117A patent/IL233117A/en active IP Right Grant
- 2014-06-18 CO CO14132584A patent/CO6990717A2/es unknown
- 2014-06-19 CR CR20140294A patent/CR20140294A/es unknown
- 2014-06-20 CU CU2014000072A patent/CU20140072A7/es unknown
- 2014-06-20 GT GT201400131A patent/GT201400131A/es unknown
- 2014-06-20 PH PH12014501417A patent/PH12014501417A1/en unknown
- 2014-07-18 EC ECIEPI20149999A patent/ECSP14009999A/es unknown
-
2015
- 2015-12-21 US US14/976,998 patent/US9763952B2/en active Active
-
2018
- 2018-02-22 CY CY20181100215T patent/CY1119939T1/el unknown
- 2018-03-05 HR HRP20180384TT patent/HRP20180384T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA37142A3 (fr) | Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine | |
MA34644B1 (fr) | Dérivés de pyrazole aminopyrimidine en tant que modulateurs du lrrk2 | |
MA38922A2 (fr) | Dérivés de quinolizine substitués utiles en tant qu'inhibiteurs de l'integrase du vih | |
MA38647B1 (fr) | Dérivés 11-hydroxyle d'acides biliaires et leurs conjugués d'acides aminés en tant que modulateurs du récepteur de farnésoïde x | |
MA37519B1 (fr) | Composés et compositions pour inhiber l'activité d'abl1, abl2 et bcr-abl1 | |
MA35086B1 (fr) | Compose de triazolopyridine | |
MA37959A2 (fr) | Dérivés de 5-phénoxy-3h-pyrimidin-4-one et leur utilisation en tant qu'inhibiteurs de la transcriptase inverse du vih | |
MA34819B1 (fr) | Dérivés bicyclo[3.2.1]octylamide et leurs utilisations | |
MA35833B1 (fr) | Dérivés de bétuline | |
EA201690019A1 (ru) | Производное аминотриазина и содержащая его фармацевтическая композиция | |
MA40225B1 (fr) | Composés dihydroisoquinolinone substitués | |
MA31741B1 (fr) | Derives fongicides de 2-alkylthio-2-quinolinyloxy- acetamide | |
MA37886B1 (fr) | Nouvelles pyridinones bicycliques | |
MA39707A (fr) | Dérivés de 1,2-dihydro-3h-pyrrolo [1,2-c]imidazol-3-one et leur utilisation comme agents antibactériens | |
MA35184B1 (fr) | Antagonistes de trpv4 | |
MA38645B1 (fr) | Nouveaux inhibiteurs de cyp17/antiandrogènes | |
MA39165A1 (fr) | Dérivés de benzimidazole-proline pour leurs utilisations dans le traitement du syndrome des etats crepusculaires | |
MA35893B1 (fr) | Dérivés d'amide hétérocyclique comme antagonistes du récepteur p2x7 | |
MA31229B1 (fr) | Composés de 6-benzyl-2, 3,4, 7-tétrahydro-indolo [2, 3-c] quinoline utiles en tant qu'inhibiteurs de pde5 | |
MA35742B1 (fr) | Dérivés de n- (4 -quinolinylmethyl) sulfonamide et leur utilisation en tant qu'antihelminthiques | |
MA38679B1 (fr) | Modulateurs du récepteur de cxcr7 | |
MA34098B1 (fr) | Utilisation de nouveaux inhibiteurs pan-cdk pour le traitement de tumeurs | |
UA107455C2 (uk) | Похідні індолу як протиракові агенти | |
MA37896A1 (fr) | Azahétérocycles utilisés comme inhibiteurs de bir2 et/ou bir3 | |
MA33760B1 (fr) | Dérivés spirolactames et leurs utilisations |